With Migraine, as with many other diseases and conditions, there are fewer medications that have been approved by the FDA for children than there are for adults. Much of this is because we naturally want to protect children, so researchers are reluctant to conduct clinical trials involving children, at least until after a medication has been used by adults for a significant period of time.
In December, the FDA granted a supplemental new drug application for the triptan Maxalt for broader use. It is now approved to treat Migraine attacks in children from 6- to 17-years-old. Up until this point, there hasn't been an abortive medication approved for use in the 6- to 12-year-old group. Axert has been approved for adolescents, 12- to 17-years-old for a few years, and it's great news that there finally is an abortive medication for younger Migraineurs.
Maxalt, as all triptans, should only used after the diagnosis of Migraine has been made. The dosage for children is weight dependant, meaning children who weigh less than 88 pounds are to take one 5-mg dose of Maxalt in a 24-hour period. Children who weigh more than 88 pounds can take 10 mgs of Maxalt, but again, only a single dose in a 24-hour period. Currently there is no information on the safety and efficacy of children taking more than a single dose of Maxalt within a 24-hour period.
Parents can now have a conversation with their doctor to see if Maxalt is a good medication to add to their child's Migraine management plan. Will you speak with you child's doctor?
Katz, Russell, MD.Department of Health and Human Services. "Supplemental Approval letter to Merck Research Laboratories." FDA: Division of Neurology Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research. December 16, 2011.
Merck Sharp & Dohme Corp. "Patient Information Maxalt and Maxalt-MLT rizatriptan benzoate." Merck & Co., Inc. December, 2012.
Thanks for reading and feel well,
visit my blog, Migraine and Other Headache Disorders
© HealthCentral Network, 2012.
Last updated March 21, 2012
Published On: March 22, 2012